Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.
Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts.
Oral Dis. 2019 Jun;25 Suppl 1(Suppl 1):64-78. doi: 10.1111/odi.13087.
To identify the prognostic biomarker candidates for stratification and long-term surveillance of oral leukoplakia progressing to cancer via a systematic literature review.
Systematic searches with no date restrictions were conducted on March 29, 2018, targeting the databases PubMed (Ovid), EMBASE (Ovid), EBM (Ovid), and Web of Science (ISI). Bias was assessed using the Quality in Prognosis Studies tool. Biomarkers were stratified based on hallmarks of cancer.
Inclusion criteria were met by 25 of 3,415 studies. A range of biomarkers were evaluated experimentally for risk stratification, prognosis, and surveillance of oral leukoplakia in tissue, blood, and saliva. However, the studies were highly heterogeneous and require further validation. Biomarkers reported in these studies included inflammatory or oxidative markers, growth factors, ion channels, genetic and cellular regulatory factors, and epigenetic biomarkers. Studies tended to include small sample sizes, under-reported or variably reported histopathological data, did not address potential confounding, reported limited/variable follow-up data, or lacked a control group. Inclusion of subsets from chemoprevention trials may have introduced bias regarding reported malignant transformation rates and accuracy of prognostic biomarkers.
This review identified insufficient longitudinal evidence to support validated prognostic biomarkers for oral leukoplakia. Further studies are needed to identify molecular targets with the potential to mitigate risk of malignant transformation.
通过系统文献回顾,确定用于口腔白斑癌变风险分层和长期监测的预后生物标志物候选物。
无日期限制的系统搜索于 2018 年 3 月 29 日在数据库 PubMed(Ovid)、EMBASE(Ovid)、EBM(Ovid)和 Web of Science(ISI)上进行。使用预后研究质量工具评估偏倚。根据癌症特征对生物标志物进行分层。
符合纳入标准的研究有 3415 项中的 25 项。在组织、血液和唾液中,对多种生物标志物进行了风险分层、预后和口腔白斑监测的实验评估。然而,这些研究高度异质,需要进一步验证。这些研究中报告的生物标志物包括炎症或氧化标志物、生长因子、离子通道、遗传和细胞调节因子以及表观遗传生物标志物。研究往往样本量小,组织病理学数据报告不足或可变,未解决潜在的混杂因素,报告的随访数据有限/可变,或缺乏对照组。化学预防试验的亚组纳入可能会对报告的恶性转化率和预后生物标志物的准确性产生偏倚。
本综述确定了用于口腔白斑的经充分验证的预后生物标志物的证据不足。需要进一步的研究来确定具有减轻恶性转化风险潜力的分子靶标。